ArticleAnnals of the rheumatic diseases2022

Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.

No numbers read from the abstract.

Not cited yet